This study is testing the effectiveness of adding a type of known as a to androgen-deprivation therapy for men with prostate cancer that has become resistant to standard . NOTE: This study is no longer enrolling people.

This Study is Open To:

NOTE: This study is no longer enrolling people.

This Study is NOT Open To:

NOTE: This study is no longer enrolling people.

Study Contact Information:

For additional information, please contact:
Arpit Rao, MD 713-798-4508 arpit.rao@bcm.edu

Study Contact Information:

Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy

Study Contact Information:

About this Study

This Study is Open To:

This Study is NOT Open To:

Study Contact Information:

Knowledge Can Save Lives